LAUSR

2016 Published by Elsevier Ltd. Although a number of seemingly disparate measures are being used to evaluate different aspects of vaccine supply chain operations, it may be unclear how they fit together and may overlap. Through our work on vaccine supply chains over the past eight years, our HERMES Team (1) assembled a list of measures that have been used (defined in Appendix A) [1,2]; (2) determined how these measures relate to one another; (3) grouped the measures into those that represent the supply side, demand side, and four domains that incorporate both (agility, costs, resource utilization, and demand fulfillment); and (4) added arrows to represent the relationships between the measures, with each connection labeled as positive (i.e. as one component increases, the other component also increases) or negative (i.e. as one component increases, the other decreases). Fig. 1 shows how some measures are actually calculated or derived from other measures (e.g. total cost per dose administered incorporates logistics costs, vaccine procurement costs, and doses administered). With this map, decision makers such as immunization program managers, ministries of health, and non-governmental organizations can determine whether they are collecting duplicative information, missing measuring certain domains, or could use alternative measures to capture the same or more information. Acknowledgments This work was supported by the Bill and Melinda Gates Foundation, the Agency for Healthcare Research and Quality (AHRQ) via Grant R01HS023317, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Office of Behavioral and Social Sciences Research (OBSSR) and the Global Obesity Prevention Center (GOPC) via Grant U54HD070725 and NICHD via U01HD086861. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The authors would like to acknowledge Raja Rao, Anna Rapp, Kaleb Brownlow at the Bill and Melinda Gates Foundation for their guidance. Appendix A. Supplementary material Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.vaccine.2016.11. 025.